Evogene (NASDAQ:EVGN – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Evogene to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Volatility & Risk
Evogene has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Evogene’s competitors have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.
Insider and Institutional Ownership
10.4% of Evogene shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Evogene and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Evogene | $3.85 million | -$8.48 million | -0.30 |
| Evogene Competitors | $727.46 million | $13.11 million | -15.18 |
Evogene’s competitors have higher revenue and earnings than Evogene. Evogene is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of current ratings for Evogene and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
| Evogene Competitors | 9839 | 15124 | 45438 | 1588 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 103.07%. Given Evogene’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Evogene has less favorable growth aspects than its competitors.
Profitability
This table compares Evogene and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evogene | -694.18% | -156.53% | -86.80% |
| Evogene Competitors | -12,346.73% | -197.60% | -30.56% |
Summary
Evogene competitors beat Evogene on 9 of the 13 factors compared.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
